Neuronetics Insider Activity: CFO’s RSU Sale, Mixed Buying, and CEO’s Massive Purchase Highlight Tax Moves, Not Market Fears

Insider Selling at a Time of Volatility

On March 19, 2026, CFO and Treasurer Steven Pfanstiel sold 16,431 shares of Neuronetics Inc. at an average price of $1.34—well below the $1.46 market price that day. The sale was linked to the exercise of a performance‑restricted stock unit (RSU) award and was described as a “non‑discretionary” tax‑withholding transaction. While the transaction size is modest relative to the company’s market capitalization, it reflects a routine tax‑planning move rather than a signal of confidence—or lack thereof—in the firm’s prospects.

What Investors Should Take Away

The broader insider landscape paints a picture of cautious activity. CEO Keith Sullivan and EVP‑CLO William Macan have also sold shares in the same week, with Macan offloading 16,005 shares and Sullivan 46,289 shares. Conversely, the company’s CEO, Daniel Reuvers, is buying a large block of 1.5 million shares, and other insiders such as Jorey Chernett are adding to their positions. The mixed buying and selling pattern suggests that insiders are managing personal cash needs and tax obligations while maintaining long‑term commitments to Neuronetics’ pipeline.

From an equity‑holder standpoint, the current transaction does not raise red flags. The stock’s recent performance—an 18.78 % weekly jump but a 64 % annual decline—indicates that the market is still grappling with valuation concerns. The price‑to‑earnings ratio of –1.92 underlines that the company is operating at a loss, which is typical for a medical‑device developer still in the early commercialization stage. As long as insider buying continues to offset selling, confidence in the company’s strategy remains largely intact.

A Profile of Steven Pfanstiel

Pfanstiel’s transaction history shows a pattern of significant purchases in July 2025 and December 2025, where he bought 400,000 shares in two separate trades, raising his holdings to 570,212 shares. These purchases occurred when the stock was trading around $1.00—well below the current price—suggesting a belief in upside potential. His most recent sale is purely tax‑related, not a strategic exit. Compared to peers, his activity is moderate; other insiders have executed larger trades, but none have sold a comparable volume in a single transaction in recent weeks.

Implications for the Company’s Future

Neuronetics remains a niche player in the neuro‑health sector, with a product portfolio that has yet to generate sustainable revenues. The company’s 52‑week high of $4.85 and low of $0.80 illustrate significant volatility, while the current price of $1.60 is only 33 % of the peak. Insider actions that balance selling for cash flow with buying for future upside are a typical governance pattern for small biotech firms. The recent RSU sale signals that executives are being rewarded for performance milestones, which may reinforce management’s long‑term focus.

For investors, the key takeaway is that insider activity is largely procedural rather than prescient. The firm’s valuation remains depressed, but ongoing insider purchases indicate that leadership retains faith in the therapeutic pipeline. As the company advances clinical milestones and seeks broader market acceptance, a sustained buying trend from insiders could serve as a positive barometer for future share price recovery.